Adaptive Biotechnologies Corporation
ADPTHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeAdaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company carries a $3.67B market cap, placing it firmly in the mid-cap category. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Market Cap
$3.67B
Beta
2.07
P/E (TTM)
—
P/E (Fwd)
-95.99
EPS (TTM)
$-0.34
EPS (Fwd)
$-0.24
ROE
-24.0%
ROA
-5.7%
Cash
$218.3M
Total Debt
$208.2M
Free CF
$16.1M
52W Change
111.5%
Annual Financials
Cash vs Debt
Adaptive Biotechnologies Corporation holds $218.3M in cash against $208.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $16.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -24.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $154.3M (2021) to $277.0M (2025), reflecting a 79% increase over the period.
Adaptive Biotechnologies Corporation's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Adaptive Biotechnologies Corporation and its sector.